Analysts predict that Global Blood Therapeutics Inc (NASDAQ:GBT) will report ($0.87) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Global Blood Therapeutics’ earnings. The highest EPS estimate is ($0.05) and the lowest is ($1.06). Global Blood Therapeutics reported earnings of ($0.78) per share in the same quarter last year, which indicates a negative year over year growth rate of 11.5%. The company is scheduled to announce its next quarterly earnings report on Thursday, August 1st.

On average, analysts expect that Global Blood Therapeutics will report full-year earnings of ($3.58) per share for the current fiscal year, with EPS estimates ranging from ($4.14) to ($0.87). For the next fiscal year, analysts expect that the company will post earnings of ($2.87) per share, with EPS estimates ranging from ($4.25) to $0.26. Zacks’ EPS calculations are an average based on a survey of research analysts that cover Global Blood Therapeutics.

Global Blood Therapeutics (NASDAQ:GBT) last posted its earnings results on Wednesday, May 8th. The company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.07.

Several research firms recently weighed in on GBT. BidaskClub raised shares of Global Blood Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, May 10th. Zacks Investment Research cut shares of Global Blood Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, March 4th. Wedbush reissued an “outperform” rating and issued a $107.00 target price on shares of Global Blood Therapeutics in a research report on Tuesday. ValuEngine raised shares of Global Blood Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday, April 1st. Finally, HC Wainwright set a $150.00 price target on Global Blood Therapeutics and gave the company a “buy” rating in a research note on Friday, April 12th. Three research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. Global Blood Therapeutics has a consensus rating of “Buy” and an average target price of $88.29.

Global Blood Therapeutics stock traded down $1.43 during midday trading on Tuesday, reaching $55.81. 1,226,493 shares of the stock traded hands, compared to its average volume of 663,156. The company has a quick ratio of 14.51, a current ratio of 14.51 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $3.23 billion, a price-to-earnings ratio of -16.37 and a beta of 1.77. Global Blood Therapeutics has a fifty-two week low of $30.15 and a fifty-two week high of $63.00.

Hedge funds and other institutional investors have recently modified their holdings of the business. Truvestments Capital LLC bought a new stake in shares of Global Blood Therapeutics in the 1st quarter valued at approximately $33,000. Kore Private Wealth LLC purchased a new position in shares of Global Blood Therapeutics during the 1st quarter valued at about $53,000. Lindbrook Capital LLC purchased a new position in shares of Global Blood Therapeutics during the 4th quarter valued at about $55,000. Strs Ohio purchased a new position in shares of Global Blood Therapeutics during the 4th quarter valued at about $65,000. Finally, Bank of Montreal Can raised its holdings in shares of Global Blood Therapeutics by 61.9% during the 4th quarter. Bank of Montreal Can now owns 1,582 shares of the company’s stock valued at $65,000 after buying an additional 605 shares in the last quarter.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.

See Also: What is the Producer Price Index (PPI)?

Get a free copy of the Zacks research report on Global Blood Therapeutics (GBT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.